Clinical Trial

Long Term Follow-up Study for Subjects Administered CLBR001

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
The goal of this Long Term Follow-Up observational study is to monitor subjects who have received CLBR001, a lentiviral vector based chimeric antigen receptor, for delayed adverse events that may be associated with human gene therapies. Participants will be followed for 15 years post-gene therapy administration date for safety and efficacy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-12; most recent amendment 2026-04-02.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-09-04
Trial Details
NCT Number NCT06882317
Lead Sponsor Calibr, a division of Scripps Research
Conditions Long Term Follow-Up
Enrollment 40 participants
Start Date 2025-08-28
Primary Completion 2044-02 (estimated)
Study Completion 2044-02 (estimated)
Updated on ClinicalTrials.gov 2026-04-08